This study focuses on patients with recurrent high grade glioma who have decided to have surgery to remove their tumor. In order to participate in this study, the tumor recurrence must measure less than 6 cm in its greatest dimension and the surgeon estimates that at least 80% of the tumor can be removed at surgery. Immediately following removal (“resection”) of the tumor, Toca 511 will be injected into the wall of the resection cavity. Approximately 4 weeks after injection subjects will begin a course of oral Toca FC. If tolerated, these courses of Toca FC will be repeated. The focus of this study is to assess the safety and tolerability of Toca 511 & Toca FC. Gadolinium-enhanced MRI scan will be performed every two months for 6 months to assess the effect of treatment.
A patient may qualify for this study if the patient:
- Has a recurrent high grade glioma (Grade 3 or Grade 4)
- Has had prior surgery, radiation and chemotherapy
- Is at least 18 years of age